| Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study H Miller, D Harman, GP Aithal, P Manousou, JF Cobbold, R Parker, ... BMJ open 14 (1), e074918, 2024 | | 2024 |
| Featured Cover MJ Mayo, JM Vierling, CL Bowlus, C Levy, GM Hirschfield, GW Neff, ... Alimentary Pharmacology & Therapeutics 59 (2), i-i, 2024 | | 2024 |
| Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis MJ Mayo, JM Vierling, CL Bowlus, C Levy, GM Hirschfield, GW Neff, ... Alimentary pharmacology & therapeutics 59 (2), 186-200, 2024 | 7 | 2024 |
| National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022 W Li, D Sheridan, S McPherson, W Alazawi, K Abeysekera, T Marjot, ... JHEP Reports 5 (12), 100897, 2023 | 2 | 2023 |
| The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease S Colosimo, H Miller, D Koutoukidis, T Marjot, G Tan, D Harman, G Aithal, ... Endocrine Abstracts 94, 2023 | | 2023 |
| Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests M Roux, C Costentin, J Chaigneau, C Fournier-Poizat, A Trylesinski, ... Springer Science and Business Media LLC, 2023 | | 2023 |
| Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review H Miller, S Colosimo, W Li, J Cobbold, W Alazawi, D Harman, G Aithal, ... Journal of Hepatology 78, S708, 2023 | | 2023 |
| The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK W Li, D Sheridan, S Mcpherson, W Alazawi Journal of Hepatology 78, S624, 2023 | | 2023 |
| O19 the National audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK W Li, D Sheridan, S McPherson, W Alazawi Gut 72 (Suppl 2), A9-A10, 2023 | 1 | 2023 |
| Open‐label, clinical trial extension MJ Mayo, JM Vierling, CL Bowlus, C Levy, G Hirschfield, A Stephen, ... | | 2023 |
| P04 Pilot study to identify undiagnosed NAFLD with moderate to advanced fibrosis in a primary care population T Harrop, J Boorer, R Maynard, K Hirwa, D Sheridan Gut 71 (Suppl 3), A33-A34, 2022 | | 2022 |
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, ... Journal of hepatology 77 (2), 353-364, 2022 | 48 | 2022 |
| Autoantibodies to apolipoprotein A-1 in chronic hepatitis C infection: a role in hepatic fibrosis and cirrhosis? S Bridge, S Pagano, D Sheridan, J Lodge, M Cramp, S Taylor-Robinson, ... Journal of Hepatology 77, S493-S494, 2022 | | 2022 |
| Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis DA Sheridan, IT Shawa, EL Thomas, DJ Felmlee, SH Bridge, D Neely, ... Scientific Reports 12 (1), 5562, 2022 | 11 | 2022 |
| Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype AD Dhanda, D Felmlee, P Boeira, P Moodley, H Tan, LDP Scalioni, K Lilly, ... Immunobiology 227 (2), 152185, 2022 | 6 | 2022 |
| Lipidomics and body fat composition analysis characterises specific differences in cholesterol metabolism and steatosis between hepatitis C virus genotypes 1 and 3 DA Sheridan, IT Shawa, EL Thomas, DJ Felmlee, SH Bridge, D Neely, ... | | 2021 |
| Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis D Petroff, V Blank, PN Newsome, CS Voican, M Thiele, V de Lédinghen, ... The Lancet Gastroenterology & Hepatology 6 (3), 185-198, 2021 | 183 | 2021 |
| Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes M Ankcorn, B Said, D Morgan, AM Elsharkawy, J Maggs, S Ryder, ... Journal of viral hepatitis 28 (2), 420-430, 2021 | 15 | 2021 |
| Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes D Petroff, V Blank, PN Newsome, CS Voican, M Thiele, V de Lédinghen, ... | | 2021 |
| P22 Obeticholic acid improves transaminases in patients with non-alcoholic steatohepatitis: results from the 18-month interim analysis of the REGENERATE study M Allison, D Sheridan, K Digpal Gut 69 (Suppl 1), A18-A18, 2020 | | 2020 |
Margaret BassendineVerified email at ncl.ac.uk